BHCM
CLYM

Brevan Howard Capital Management’s Climb Bio CLYM Stock Holding History

Brevan Howard Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-56,624
Closed -$388K – 2676
2026
Q1 		$388K Buy
+56,624
New +$327K ﹤0.01% 1450

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Brevan Howard Capital Management's CLYM Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 56,624 shares — an estimated $388K sold.

Brevan Howard Capital Management first reported a position in CLYM in Q1 2026 and held it in 1 quarter. The position peaked at $388K in Q1 2026. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 56,624 Climb Bio shares in Q2 2026, an estimated $388K.
  • Brevan Howard Capital Management first reported a position in Climb Bio in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Climb Bio position peaked at $388K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.